Clinical Trial Update: Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating neratinib with or without fulvestrant in HER2-positive, estrogen receptor-positive metastatic breast cancer has been terminated, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• Nerlynx (neratinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-03-21